Smart & Biggar successfully represented Boehringer Ingelheim in a s. 6(1) action under the Patented Medicines (Notice of Compliance) Regulations regarding the use of nintedanib in the prevention or treatment of idiopathic pulmonary fibrosis.
Read more about this case via our article "Boehringer Ingelheim succeeds in nintedanib PMNOC action against JAMP".